EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

New Delhi Metallo-Beta-Lactamase Inhibitors: A Systematic Scoping Review

Lutfun Nahar, Hideharu Hagiya iD, Kazuyoshi Gotoh, Md Asaduzzaman, Fumio Otsuka iD

Journal of Clinical Medicine · 18.07.2024 · 13 (14) · 4199

DOI: 10.3390/jcm13144199 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.07.2024. Verfasst von Lutfun Nahar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Among various carbapenemases, New Delhi metallo-beta-lactamases (NDMs) are recognized as the most powerful type capable of hydrolyzing all beta-lactam antibiotics, often conferring multi-drug resistance to the microorganism. The objective of this review is to synthesize current scientific data on NDM inhibitors to facilitate the development of future therapeutics for challenging-to-treat pathogens.

Methods

Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Reviews, we conducted a MEDLINE search for articles with relevant keywords from the beginning of 2009 to December 2022. We employed various generic terms to encompass all the literature ever published on potential NDM inhibitors.

Results

Out of the 1760 articles identified through the database search, 91 met the eligibility criteria and were included in our analysis. The fractional inhibitory concentration index was assessed using the checkerboard assay for 47 compounds in 37 articles, which included 8 compounds already approved by the Food and Drug Administration (FDA) of the United States. Time-killing curve assays (14 studies, 25%), kinetic assays (15 studies, 40.5%), molecular investigations (25 studies, 67.6%), in vivo studies (14 studies, 37.8%), and toxicity assays (13 studies, 35.1%) were also conducted to strengthen the laboratory-level evidence of the potential inhibitors. None of them appeared to have been applied to human infections.

Conclusions

Ongoing research efforts have identified several potential NDM inhibitors; however, there are currently no clinically applicable drugs. To address this, we must foster interdisciplinary and multifaceted collaborations by broadening our own horizons.

Schlagwörter

Stichwörter der Autor:innen

antimicrobial resistancecarbapenem-resistant Enterobacteralescarbapenemase-producing Enterobacteralescombinationmetallo-beta-lactamasesynergy

Autor:innen und Institutionen

  • Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
  • Department of Infectious Diseases, Okayama University Hospital, Okayama 700-8558, Japan.
  • Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.

ORCID-Profile: Hideharu Hagiya, Fumio Otsuka

Zitieren

APA

Nahar, L., Hagiya, H., Gotoh, K., Asaduzzaman, M., & Otsuka, F. (2024). New Delhi Metallo-Beta-Lactamase Inhibitors: A Systematic Scoping Review. Journal of Clinical Medicine, 13(14), 4199. https://doi.org/10.3390/jcm13144199

Vancouver

Nahar L, Hagiya H, Gotoh K, Asaduzzaman M, Otsuka F. New Delhi Metallo-Beta-Lactamase Inhibitors: A Systematic Scoping Review. Journal of Clinical Medicine. 2024;13(14):4199. doi:10.3390/jcm13144199

BibTeX
@article{Nahar2024,
  author = {Nahar, Lutfun and Hagiya, Hideharu and Gotoh, Kazuyoshi and Asaduzzaman, Md and Otsuka, Fumio},
  title = {New Delhi Metallo-Beta-Lactamase Inhibitors: A Systematic Scoping Review},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {14},
  pages = {4199},
  doi = {10.3390/jcm13144199}
}
Kostenlos starten →